

Supporting information

Synthesis of benzoxazoles, benzimidazoles, and benzothiazoles using Brønsted acidic ionic liquid gel as an efficient heterogeneous catalyst under solvent-free condition.

The Thai Nguyen,^a Xuan-Trang Thi Nguyen,^a Thuy-Linh Ho Nguyen,^{a,b} Phuong Hoang Tran^{a,*}

^a Department of Organic Chemistry, Faculty of Chemistry, University of Science, Vietnam National University – Ho Chi Minh City, 721337, Viet Nam.

^b Center for Innovative Materials and Architectures, Vietnam National University – Ho Chi Minh City, 721337, Viet Nam

*Corresponding author: phone number: +84-903-706-762; e-mail: thphuong@hcmus.edu.vn

Table of contents

Section S1. Preparation and characterization of BAIL gel	S2-S5
Section S2. Spectral data	S6-S16
Section S3. ¹H, ¹³C NMR and MS spectra	S17-S44
Section S4. References	S45-S46

Section S1. Preparation and characterization of BAIL gel

All commercially available reagent-grade chemicals were purchased from chemical suppliers and used as received without further purification unless otherwise noted.

Preparation of 1-(4-sulfonic acid)butyl-3-methylimidazolium hydrogen sulfate ionic liquid (BAIL)

1-Methylimidazolium (123 mg, 1.5 mmol) and 1,4-butane sultone (0.204 mg, 1.5 mmol) were added into a glass-tube with Teflon cap. After 1 h of sonication, the reaction mixture was washed with diethyl ether (6 x 5 mL) and dried at 80 °C in 60 min. The obtained witterion (1.5 mmol, 327 mg) was then mixed with sulfuric acid (147 mg, 1.5 mmol). The resulting mixture was sonicated at room temperature for 2 h. The crude product was then washed with diethyl ether (10 x 3 mL) and dried under vacuum at 80 °C in 60 min. The BAIL was characterized by FT-IR, ¹H and ¹³C NMR, HRMS (ESI).

1-(4-sulfonic acid)butyl-3-methylimidazolium hydrogen sulfate ionic liquid. FT-IR (KBr, cm⁻¹): 3410, 1639, 1457, 1171, 1042, 752; ¹H NMR (500 MHz, D₂O) δ 8.59 (s, 1H), 7.35 (t, *J* = 1.7 Hz, 1H), 7.29 (t, *J* = 1.7 Hz, 1H), 4.10 (t, *J* = 7.0 Hz, 2H), 3.75 (s, 3H), 2.83 (t, *J* = 8.0, 2H), 1.82 (m, 2H), 1.60 (m, 2H); ¹³C NMR (125 MHz, D₂O) δ 135.9, 123.6, 122.1, 50.0, 48.9, 35.7, 28.1, 20.9; HRMS (ESI) *m/z* calcd for [M]⁺ C₈H₁₅N₂O₃S⁺ 219.0798, found 219.0783.

Preparation of BAIL gel

The BAIL (3.1635 g, 10 mmol), TEOS (3.125 g, 15 mmol) and ethanol (1.380 g, 30 mmol) were added to a 20 mL round-bottom flask and stirred for 10 min until the mixture became homogeneous. The mixture was left to stand and gelled in a week. The gel was then subjected to aging for 3 weeks. After that, the gel was transferred into a 100 mL round-bottom flask containing 50 mL of ethanol and heated to reflux for 2 h. The BAIL gel was washed with toluene (5 x 10 mL) and dried under vacuum for 3 h. It was finally characterized by FT-IR, TGA, ICP-OES, SEM, and EDS.




Figure S1. FT-IR spectra of BAIL (a), BAIL gel (b) and BAIL gel after the fifth recovery (c).




Figure S2. TG analysis of BAIL gel




Figure S3. The SEM image of BAIL gel.





Figure S4. EDS spectrum of BAIL gel.

Section S2. Spectral data

2-Phenylbenzoxazole (1)^{1,2}



Melting point: 102-103.5 °C


FT-IR (KBr, 4000-400 cm⁻¹) 3059, 2925, 2854, 1775, 1615, 1551, 1475, 1448, 1285, 1240.

¹H NMR (500 MHz, CDCl₃) δ 8.31-8.22 (m, 2H), 7.82-7.75 (m, 1H), 7.61-7.56 (m, 1H), 7.55-7.50 (m, 3H), 7.40-7.33 (m, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 163.2, 150.9, 142.2, 131.7, 129.0, 127.8, 127.3, 125.3, 124.7, 120.1, 110.7.

GC-MS (EI, 70 eV) *m/z* 195 ([M]⁺).

2-(*p*-Tolyl)benzoxazole (2)¹⁻³



Melting point: 113-114.5 °C


FT-IR (KBr, 4000-400 cm⁻¹) 3056, 2920, 2854, 1728, 1620, 1554, 1499, 1450, 1242.

¹H NMR (500 MHz, CDCl₃) δ 8.17-8.13 (m, 2H), 7.77-7.74 (m, 1H), 7.58-7.50 (m, 1H), 7.35-7.31 (m, 4H), 2.44 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 163.5, 150.8, 142.3, 142.2, 129.8, 127.8, 125.1, 124.7, 124.5, 120.0, 110.6, 21.8.

GC-MS (EI, 70 eV) *m/z* 209 ([M]⁺).

2-(4-Methoxyphenyl)benzoxazole (3)²



Melting point: 103-104.5 °C


FT-IR (KBr, 4000-400 cm⁻¹) 3050, 2924, 2849, 1615, 1501, 1450, 1420, 1244.

¹H NMR (500 MHz, CDCl₃) δ 8.23-8.17 (m, 2H), 7.75-7.73 (m, 1H), 7.56-7.54 (m, 1H), 7.35-7.29 (m, 2H), 7.05-7.01 (m, 2H), 3.89 (s, 3H).

^{13}C NMR (125 MHz, CDCl_3) δ 163.3, 162.6, 150.8, 142.1, 129.7, 124.8, 124.7, 119.7, 119.7, 114.6, 110.6, 55.6.

GC-MS (EI, 70 eV) m/z 225 ($[\text{M}]^+$).

2-(4-*tert*-Butylphenyl)benzoxazole (4)²



Melting point: 107-108 °C


FT-IR (KBr, 4000-400 cm^{-1}) 3059, 2927, 1728, 1547, 1452, 1429, 1287, 1239.

^1H NMR (500 MHz, CDCl_3) δ 8.21-8.16 (m, 2H), 7.78-7.75 (m, 1H), 7.60-7.56 (m, 1H), 7.56-7.54 (m, 2H), 7.37-7.32 (m, 2H), 1.38 (s, 9H).

^{13}C NMR (125 MHz, CDCl_3) δ 163.4, 155.4, 150.8, 142.1, 127.7, 126.1, 125.1, 124.7, 124.4, 120.0, 110.7, 35.2, 31.3.

GC-MS (EI, 70 eV) m/z 251 ($[\text{M}]^+$).

2-(4-Fluorophenyl)benzoxazole (5)²



Melting point: 99-99.5 °C


FT-IR (KBr, 4000-400 cm^{-1}) 3061, 2925, 1619, 1584, 1582, 1542, 1473, 1448, 1247, 1225.

^1H NMR (500 MHz, CDCl_3) δ 8.30-8.22 (m, 2H), 7.80-7.72 (m, 1H), 7.60-7.53 (m, 1H), 7.40-7.32 (m, 2H), 7.23-7.17 (m, 2H).

^{13}C NMR (125 MHz, CDCl_3) δ 166.0 (s), 164.0(s), 162.3 (s), 150.9 (s), 142.2 (s), 130.0 (d, $J = 255.1$ Hz), 130.0 (d, $J = 8.8$ Hz), 125.0 (d, $J = 59.5$ Hz), 123.67 (d, $J = 3.2$ Hz), 120.14 (s), 116.3 (d, $J = 44.0$ Hz), 110.7 (s).

GC-MS (EI, 70 eV) m/z 213 ($[\text{M}]^+$).

2-(4-Chlorophenyl)benzoxazole (6)²



Melting point: 148-150 °C


FT-IR (KBr, 4000-400 cm^{-1}) 3067, 2922, 1725, 1607, 1451, 1428, 1237.

^1H NMR (500 MHz, CD_3CO) δ 8.26-8.22 (m, 2H), 7.77-7.75 (m, 1H), 7.70-7.69 (m, 1H), 7.65-7.62 (m, 2H), 7.42 (pd, $J = 7.5, 2.0$ Hz, 2H).

^{13}C NMR (125 MHz, CD_3CO) δ 161.7, 150.8, 142.1, 137.2, 129.3, 129.0, 125.9, 125.6, 124.9, 120.0, 110.7.

GC-MS (EI, 70 eV) m/z 229.5 ($[\text{M}]^+$).

2-(4-Nitrophenyl)benzoxazole (7)³



Melting point: 156-157 $^{\circ}\text{C}$


FT-IR (KBr, 4000-400 cm^{-1}) 2925, 2854, 1678, 1610, 1534, 1449, 1237.

^1H NMR (500 MHz, CDCl_3) δ 8.15 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.89 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.83-7.80 (m, 1H), 7.74 (td, $J = 8.0, 1.0$ Hz, 1H), 7.69 (td, $J = 8.0, 1.0$ Hz, 1H), 7.59-7.57 (m, 1H), 7.42-7.37 (m, 2H).

^{13}C NMR (125 MHz, CDCl_3) δ 158.9, 151.2, 141.7, 132.4, 132.0, 131.6, 126.2, 125.1, 124.3, 121.7, 120.9, 111.1.

GC-MS (EI, 70 eV) m/z 240 ($[\text{M}]^+$).

2-(Pyridin-4-yl)benzoxazole (8)



Melting point: 102-104 $^{\circ}\text{C}$


FT-IR (KBr, 4000-400 cm^{-1}) 3460, 2946, 1628, 878.

^1H NMR (500 MHz, CDCl_3) δ 8.82 (d, $J = 5.5$ Hz, 2H), 8.09 (d, $J = 6.0$ Hz, 2H), 7.84-7.80 (m, 1H), 7.63 (m, 1H), 7.42 (m, 2H).

^{13}C NMR (125 MHz, CDCl_3) δ 161.0, 151.1, 150.9, 141.9, 134.6, 126.5, 125.3, 121.2, 120.9, 111.1.

GC-MS (EI, 70 eV) m/z 196 ($[\text{M}]^+$)

5-Methyl-2-phenylbenzoxazole (9)²



Melting point: 112-115 °C


FT-IR (KBr, 4000-400 cm⁻¹) 2918, 1626, 1552, 1445, 1263.

¹H NMR (500 MHz, acetone-*d*₆) δ 8.25-8.23 (m, 2H), 7.62-7.59 (m, 3H), 7.57-7.56 (m, 2H), 7.24 (d, *J* = 8.5, 1H), 2.47 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 163.3, 149.2, 142.5, 134.5, 131.5, 129.0, 127.7, 127.5, 126.4, 120.1, 110.1, 21.6.

GC-MS (EI, 70 eV) *m/z* 209 ([M]⁺).

5-Methyl-2-(*p*-tolyl)benzoxazole (10)⁴



Melting point: 138-139 °C.


FT-IR (KBr, 4000-400 cm⁻¹) 3304, 2921, 2856, 1616, 1555, 1499, 1332, 1262.

¹H NMR (500 MHz, acetone-*d*₆) δ 8.11 (d, *J* = 8.0 Hz, 2H), 7.53-7.51 (m, 2H), 7.39 (d, *J* = 8.0 Hz, 2H), 7.22-7.19 (m, 1H), 2.46 (s, 3H), 2.43 (s, 3H).

¹³C NMR (125 MHz, acetone-*d*₆) δ 163.2, 149.2, 142.7, 142.3, 134.5, 129.9, 127.5, 126.3, 124.8, 119.9, 110.1, 20.9, 20.8.

GC-MS (EI, 70 eV) *m/z* 223 ([M]⁺).

5-Methyl-2-(4-*tert*-butylphenyl)benzoxazole (11)⁵



Melting point: 137-140 °C


FT-IR (KBr, 4000-400 cm⁻¹) 3107, 2963, 2930, 2871, 1729, 1621, 1532, 1460, 1269.

¹H NMR (500 MHz, acetone-*d*₆) δ 8.56 (d, *J* = 2.0 Hz, 1H), 8.34 (dd, *J* = 9.0, 2.0 Hz, 1H), 8.20 (d, *J* = 8.5 Hz, 2H), 7.92 (d, *J* = 9.0 Hz, 1H), 7.69 (d, *J* = 9.0 Hz, 2H), 2.81 (s, 3H), 1.39 (s, 9H).

¹³C NMR (125 MHz, acetone-*d*₆) δ 162.9, 155.0, 149.0, 142.5, 134.3, 127.2, 126.1, 126.0, 124.6, 119.7, 109.9, 34.7, 30.5, 20.5.

GC-MS (EI, 70 eV) *m/z* 265 ([M]⁺).

5-Methyl-2-(4-chlorophenyl)benzoxazole (12)⁴



Melting point: 150-151°C


FT-IR (KBr, 4000-400 cm⁻¹) 3102, 2930, 2875, 1759, 1635, 1530, 1462, 1272.

¹H NMR (500 MHz, acetone-*d*₆) δ 8.18 (d, *J* = 8.5 Hz, 2H), 7.55 (s, 1H), 7.50 (d, *J* = 8.5 Hz, 2H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.17 (d, *J* = 9.0 Hz, 1H), 2.49 (s, 3H).

¹³C NMR (125 MHz, acetone-*d*₆) δ 162.3, 149.2, 142.4, 137.7, 134.7, 129.3, 128.9, 126.6, 126.0, 120.1, 110.1, 21.6.

GC-MS (EI, 70 eV) *m/z* 243.5 ([M]⁺).

5-Methyl-2-(pyridin-4-yl)benzoxazole (13)



Melting point: 129-130 °C.


FT-IR (KBr, 4000-400 cm⁻¹) 3406, 2921, 1612, 1537, 1414, 1344, 1068, 808.

¹H NMR (500 MHz, acetone-*d*₆) δ 8.80 (d, *J* = 4.5 Hz, 2H), 8.07 (d, *J* = 5.0 Hz, 2H), 7.59 (s, 1H), 7.48 (d, *J* = 8.5 Hz, 1H), 7.23 (d, *J* = 8.0 Hz, 1H), 2.50 (s, 3H).

¹³C NMR (125 MHz, acetone-*d*₆) 160.8, 150.7, 149.3, 142.1, 135.2, 134.8, 127.7, 121.1, 120.6, 110.4, 21.6.

GC-MS (EI, 70 eV) *m/z* 210 ([M]⁺)

5-Chloro-2-phenylbenzoxazole (14)⁶



Melting point: 102-104 °C.


FT-IR (KBr, 4000-400 cm^{-1}) 3061, 1612, 1551, 1443, 1333, 1265.

^1H NMR (500 MHz, acetone- d_6) δ 8.23 (d, $J = 7.5$ Hz, 2H), 7.77 (d, $J = 1.5$ Hz, 1H), 7.70 (d, $J = 7.5$ Hz, 1H), 7.64-7.59 (m, 3H), 7.42 (dd, $J = 9.0, 1.5$ Hz, 1H).

^{13}C NMR (125MHz, acetone- d_6) δ 165.3, 150.6, 144.5, 133.1, 130.7, 130.2, 128.6, 127.7, 126.4, 120.7, 112.9.

GC-MS (EI, 70 eV) m/z 229.5 ($[\text{M}]^+$).

5-Chloro-2-(*p*-tolyl)benzoxazole (15)⁷



Melting point: 148-150 °C


FT-IR (KBr, 4000-400 cm^{-1}) 2953, 1610, 1551, 1479, 1448, 1258.

^1H NMR (500 MHz, acetone- d_6) δ 8.13 (d, $J = 8.0$ Hz, 2H), 7.75 (d, $J = 2.0$ Hz, 1H), 7.70 (d, $J = 9.0$ Hz, 1H), 7.40-7.33 (m, 4H), 2.44 (s, 3H).

^{13}C NMR (125 MHz, acetone- d_6) δ 165.6, 150.5, 144.6, 143.8, 130.8, 130.6, 128.6, 126.2, 125.0, 120.5, 112.8, 21.7.

GC-MS (EI, 70 eV) m/z 243.5 ($[\text{M}]^+$).

5-Chloro-2-(4-*tert*-butylphenyl)benzoxazole (16)⁸



Melting point: 137-138 °C


FT-IR (KBr, 4000-400 cm^{-1}): 2957, 2902, 2866, 1611, 1552, 1493, 1457, 1262.

^1H NMR (500 MHz, acetone- d_6) δ 8.17 (d, $J = 8.5$ Hz, 2H), 7.76 (s, 1H), 7.70 (d, $J = 8.5$ Hz, 1H), 7.66 (d, $J = 8.5$ Hz, 2H), 7.41 (dd, $J = 8.5, 2.0$ Hz, 1H), 1.38 (s, 9H).

^{13}C NMR (125 MHz, acetone- d_6) δ 165.5, 156.7, 150.6, 144.6, 130.6, 128.6, 127.2, 126.2, 125.0, 120.5, 112.8, 35.9, 31.5.

GC-MS (EI, 70 eV) m/z 285.5 ($[\text{M}]^+$).

5-Chloro-2-(4-chlorophenyl)benzoxazole (17)⁷



Melting point: 195-197°C


FT-IR (KBr, 4000-400 cm^{-1}) 2913, 1727, 1550, 1448, 1245.

^1H NMR (500 MHz, acetone- d_6) δ 8.28-8.23 (m, 2H), 7.81 (d, $J = 1.5$ Hz, 1H), 7.74 (d, $J = 8.5$ Hz, 1H), 7.69-7.65 (m, 2H), 7.46 (dd, $J = 8.5, 2.0$ Hz, 1H).

^{13}C NMR (125 MHz, acetone- d_6) δ 149.6, 143.4, 137.7, 129.8, 129.4, 129.2, 125.7, 125.5, 119.7, 111.9.

GC-MS (EI, 70 eV) m/z 285.5 ($[\text{M}]^+$).

5-Chloro-2-(pyridin-4-yl)benzoxazole (18)



Melting point: 152-153 °C.


FT-IR (KBr, 4000-400 cm^{-1}) 3431, 2922, 1612, 1568, 1539, 1449, 1057, 874.

^1H NMR (500 MHz, acetone- d_6) δ 8.83 (d, $J = 5.5$ Hz, 2H), 8.07 (dd, $J = 4.5, 1.5$ Hz, 2H), 7.80 (d, $J = 2.0$ Hz, 1H), 7.55 (d, $J = 8.5$ Hz, 1H), 7.40 (dd, $J = 8.5, 2.0$ Hz, 1H).

^{13}C NMR (125 MHz, acetone- d_6) δ 162.0, 150.8, 149.6, 143.0, 134.2, 130.9, 126.9, 121.3, 120.8, 111.9.

GC-MS (EI, 70 eV) m/z 230 ($[\text{M}]^+$)

5-Nitro-2-phenylbenzoxazole (19)⁷



Melting point: 166-169 °C.


FT-IR (KBr, 4000-400 cm^{-1}): 3105, 2925, 2853, 1709, 1604, 1526, 1463, 1348, 1286.

^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 8.68 (d, $J = 2.5$ Hz, 1H), 8.35 (dd, $J = 9.0, 2.0$ Hz, 1H), 8.26-8.24 (m, 2H), 8.06 (d, $J = 9.0$ Hz, 1H), 7.71-7.65 (m, 3H).

^{13}C NMR (125 MHz, CDCl_3) δ 165.4, 154.0, 145.1, 141.9, 132.9, 129.5, 127.8, 125.5, 121.5, 121.4, 115.8, 115.7, 111.8.

GC-MS (EI, 70 eV) m/z 240 ($[\text{M}]^+$).

5-Nitro-2-(*p*-tolyl)benzoxazole (20)⁹



Melting point: 125-126 °C.


FT-IR (KBr, 4000-400 cm^{-1}) 2923, 2850, 1695, 1628, 1515, 1416, 1328, 1250.

^1H NMR (500 MHz, acetone- d_6) δ 8.31-8.27 (m, 2H), 7.57-7.55 (m, 2H), 7.40-7.35 (m, 2H), 7.24 (d, $J = 9.0$ Hz, 1H), 2.47 (s, 3H).

^{13}C NMR (125 MHz, acetone- d_6) δ 166.7, 164.7, 150.0, 143.3, 135.5, 130.8, 130.7, 127.3, 124.8, 120.7, 117.2, 117.0, 110.9, 21.4.

GC-MS (EI, 70 eV) m/z 254 ($[\text{M}]^+$).

5-Nitro-2-(4-*tert*-butylphenyl)benzoxazole (21)¹⁰



Melting point: 136-137 °C.


FT-IR (KBr, 4000-400 cm^{-1}) 3106, 2964, 2869, 1724, 1619, 1531, 1496, 1462, 1343, 1267.

^1H NMR (500 MHz, acetone- d_6) δ 8.18-8.16 (m, 2H), 7.66-7.63 (m, 2H), 7.56-7.54 (m, 2H), 7.23-7.21 (m, 1H), 1.38 (s, 9H).

^{13}C NMR (125 MHz, acetone- d_6) δ 166.9, 157.3, 155.3, 146.4, 143.6, 132.1, 129.7, 128.7, 127.2, 124.2, 122.0, 116.4, 112.1, 35.8, 31.4.

GC-MS (EI, 70 eV) m/z 296 ($[M]^+$).

5-Nitro-2-(4-chlorophenyl)benzoxazole (22)⁷



Melting point: 215-217 °C.


FT-IR (KBr, 4000-400 cm^{-1}) 3105, 2924, 2854, 1615, 1528, 1481, 1346, 1257, 1088.

¹H NMR (500 MHz, acetone- d_6) δ 8.63 (d, $J = 2.0$ Hz, 1H), 8.39 (dd, $J = 9.0, 2.0$ Hz, 1H), 8.32-8.29 (m, 2H), 7.98 (d, $J = 9.0$ Hz, 1H), 7.71-7.70 (m, 2H).

¹³C NMR (125 MHz, acetone- d_6) δ 155.4, 130.5, 130.4, 130.3, 129.7, 125.9, 122.4, 116.7, 112.4.

GC-MS (EI, 70 eV) m/z 274.5 ($[M]^+$).

2-Phenylbenzothiazole (23)¹¹



Melting point: 111-113 °C


FT-IR (KBr, 4000-400 cm^{-1}) 3063, 1631, 1476, 1452, 1311, 1223.

¹H NMR (500 MHz, CDCl_3) δ 8.12-8.08 (m, 3H), 7.91 (d, $J = 8.0$ Hz, 1H), 7.51-7.48 (m, 4H), 7.41-7.37 (m, 1H).

¹³C NMR (125 MHz, CDCl_3) δ 168.2, 154.3, 135.2, 133.8, 131.1, 129.2, 127.7, 126.5, 125.3, 123.4, 121.8.

GC-MS (EI, 70 eV) m/z 211 ($[M]^+$).

2-(*p*-Tolyl)benzothiazole (24)¹¹



Melting point: 85-86 °C


FT-IR (KBr, 4000-400 cm^{-1}) 2920, 2855, 1605, 1477, 1308, 1216.

¹H NMR (500 MHz, CDCl₃) δ 8.07 (d, *J* = 8.5 Hz, 1H), 7.99 (d, *J* = 8.0 Hz, 2H), 7.88 (d, *J* = 8.0, 0.5 Hz, 1H), 7.50 (td, *J* = 7.0, 1.0, 1H), 7.36 (td, *J* = 7.0, 1.0, 1H), 7.29 (d, *J* = 8.0 Hz, 2H), 2.42 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 168.3, 154.3, 141.5, 135.1, 131.1, 129.8, 127.6, 126.4, 125.1, 123.2, 121.7, 21.6.

GC-MS (EI, 70 eV) *m/z* 225 ([M]⁺).

2-(4-Methoxyphenyl)benzothiazole (25)¹¹



Melting point: 121-122 °C


FT-IR (KBr, 4000-400 cm⁻¹) 2917, 1599, 1478, 1518, 1479, 1308, 1256.

¹H NMR (500 MHz, CDCl₃) δ 8.05-8.02 (m, 3H), 7.88 (d, *J* = 8.0 Hz, 1H), 7.47 (td, *J* = 8.0, 1.0 Hz, 1H), 7.35 (td, *J* = 8.0, 1.0 Hz, 1H), 7.02-6.99 (m, 2H), 3.89 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 168.0, 162.1, 154.3, 135.0, 129.3, 126.6, 126.4, 125.0, 123.0, 121.7, 114.5, 55.6.

GC-MS (EI, 70 eV) *m/z* 241 ([M]⁺).

2-Phenylbenzimidazole (26)¹²



Melting point: 293-294 °C


FT-IR (KBr, 4000-400 cm⁻¹) 3411, 1540, 1450, 1408, 967, 774.

¹H NMR (500 MHz, DMSO-*d*₆) δ 8.18 (d, *J* = 7.5 Hz, 1H), 7.60 (s, 1H), 7.57-7.55 (m, 2H), 7.51-7.48 (m, 1H), 7.22-7.19 (m, 2H).

¹³C NMR (125 MHz, DMSO-*d*₆) δ 151.2, 130.2, 129.8, 128.9, 126.4, 122.1.

GC-MS (EI, 70 eV) *m/z* 195 ([M]⁺).

2-(4-Methoxyphenyl)benzimidazole (27)¹²



Melting point: 204 °C


FT-IR (KBr, 4000-400 cm⁻¹): 3395, 3055, 1452, 1406, 1274, 741.

¹H NMR (500 MHz, DMSO-*d*₆): δ 8.49 (s, 1H), 8.05 (d, *J* = 7.5 Hz, 1H), 7.88 (d, *J* = 9Hz, 2H), 7.81 (d, *J* = 8.0 Hz, 1H), 7.47-7.41 (m, 2H), 7.17 (d, *J* = 8.5 Hz, 2H), 3.90 (s, 3H) ppm.

¹³C NMR (125 MHz, DMSO-*d*₆): δ 166.4, 163.2, 144.3, 143.7, 132.4, 132.1, 131.6, 125.1, 124.7, 124.5, 120.1, 115.0, 114.4, 55.7 ppm.

GC-MS (EI, 70 eV) *m/z* 225 ([M]⁺).

2-(4-Fluorophenyl)benzimidazole (28)¹²



Melting point: 253-254 °C

FT-IR (KBr, 4000-400 cm⁻¹) 3429, 3060, 1604, 1440, 964, 743.

¹H NMR (500 MHz, DMSO-*d*₆) δ 8.23-8.21 (m, 2H), 7.59-7.58 (m, 2H), 7.42-7.38 (m, 2H), 7.22-7.18 (m, 2H) ppm.

¹³C NMR (125 MHz, DMSO-*d*₆) δ 163.0 (d, *J* = 245.0 Hz), 150.4, 131.3, 128.7 (d, *J* = 8.75 Hz), 126.8, 122.1, 116.0, 115.9 ppm.

GC-MS (EI, 70 eV) *m/z* 213 ([M]⁺).

Section S3. ^1H , ^{13}C NMR spectroscopy




Figure S5. ^1H (top) and ^{13}C (bottom) NMR spectra of 2-phenylbenzoxazole (1).




Figure S6. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(*p*-tolyl)benzoxazole (2).




Figure S7. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(4-methoxyphenyl)benzoxazole (3).




Figure S8. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(4-*tert*-butylphenyl)benzoxazole (4).




Figure S9. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(4-fluorophenyl)benzoxazole (5).




Figure S10. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(4-chlorophenyl)benzoxazole (6).




Figure S11. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(4-nitrophenyl)benzoxazole (7).





Figure S12. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(pyridin-4-yl)benzoxazole (8).




Figure S13. ¹H (top) and ¹³C (bottom) NMR spectra of 5-methyl-2-phenylbenzoxazole (9).




Figure S14. ¹H (top) and ¹³C (bottom) NMR spectra of 5-methyl-2-(*p*-tolyl)benzoxazole (10).




Figure S15. ¹H (top) and ¹³C (bottom) NMR spectra of 5-methyl-2-(4-*tert*-butylphenyl)benzoxazole (11).





Figure S16. ¹H (top) and ¹³C (bottom) NMR spectra of 5-methyl-2-(4-chlorophenyl)benzoxazole (12).




Figure S17. ¹H (top) and ¹³C (bottom) NMR spectra of 5-methyl-2-(pyridin-4-yl)benzoxazole (13).




Figure S18. ¹H (top) and ¹³C (bottom) NMR spectra of 5-chloro-2-phenylbenzoxazole (14).




Figure S19. ¹H (top) and ¹³C (bottom) NMR spectra of 5-chloro-2-(*p*-tolyl)benzoxazole (15).




Figure S20. ¹H (top) and ¹³C (bottom) NMR spectra of 5-chloro-2-(4-*tert*-butylphenyl)benzoxazole (16).




Figure S21. ¹H (top) and ¹³C (bottom) NMR spectra of 5-chloro-2-(4-chlorophenyl)benzoxazole (17).




Figure S22. ¹H (top) and ¹³C (bottom) NMR spectra of 5-chloro-2-(pyridin-4-yl)benzoxazole (18).




Figure S23. ¹H (top) and ¹³C (bottom) NMR spectra of 5-nitro-2-phenylbenzoxazole (19).




Figure S24. ¹H (top) and ¹³C (bottom) NMR spectra of 5-nitro-2-(*p*-tolyl)benzoxazole (20).





Figure S25. ¹H (top) and ¹³C (bottom) NMR spectra of 5-nitro-2-(4-*tert*-butylphenyl)benzoxazole (21).




Figure S26. ¹H (top) and ¹³C (bottom) NMR spectra of 5-nitro-2-(4-chlorophenyl)benzoxazole (22).




Figure S27. ^1H (top) and ^{13}C (bottom) NMR spectra of 2-phenylbenzothiazole (23).




Figure S28. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(*p*-tolyl)benzothiazole (24).




Figure S29. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(4-methoxyphenyl)benzothiazole (25).





Figure S30. ^1H (top) and ^{13}C (bottom) NMR spectra of 2-phenylbenzimidazole (26).





Figure S31. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(4-methoxyphenyl)benzimidazole (27).





Figure S32. ¹H (top) and ¹³C (bottom) NMR spectra of 2-(4-fluorophenyl)benzimidazole (28).

Section S3. References

1. Teo, Y. C., Riduan, S. N., Zhang, Y. Iodine-mediated arylation of benzoxazoles with aldehydes. *Green Chem.* **15**, 2365–2368 (2013).
2. Tang, L., Guo, X., Yang, Y., Zha, Z., Wang, Z. Gold nanoparticles supported on titanium dioxide: an efficient catalyst for highly selective synthesis of benzoxazoles and benzimidazoles. *Chem. Commun.* **50**, 6145–6148 (2014).
3. Patil, M. R., Bhanushali, J. T., Nagaraja, B. M., Keri, R. S. TiO₂ZrO₂ composite: Synthesis, characterization and application as a facile, expeditious and recyclable catalyst for the synthesis of 2-aryl substituted benzoxazole derivatives. *Comptes Rendus Chim.* **21**, 399–407 (2018).
4. Ferguson, D., Rudolph, S. R. Nickel-catalyzed C–H arylation of benzoxazoles and oxazoles: benchmarking the influence of electronic, steric and leaving group variations in phenolic electrophiles. *Tetrahedron* **73**, 2196–2209 (2017).
5. Zhou, Q., Zhang, J.-F., Cao, H., Zhong, R., Hou, X.-F. Synthesis of *o*-alkenylated 2-arylbenzoxazoles via Rh-catalyzed oxidative olefination of 2-arylbenzoxazoles: scope investigation, structural features, and mechanism studies. *J. Org. Chem.* **81**, 12169–12180 (2016).
6. Gupta, R., Sahu, P. K., Sahu, P. K., Srivastava, S. K., Agarwal, D. D. Environmental benign synthesis of novel double layered nano catalyst and their catalytic activity in synthesis of 2-substituted benzoxazoles. *Catal. Commun.* **92**, 119–123 (2017).
7. Srivastava, A., Shukla, G., Singh, M. S. *p*-Toluenesulfonic acid-catalyzed metal-free formal [4+1] heteroannulation via N-H/O-H/S-H functionalization: One-pot access to 2-aryl/hetaryl/alkyl benzazole derivatives. *Tetrahedron* **73**, 879–887 (2017).
8. Reyes, H., Beltran, H. I., Rivera-Becerril, E. One pot synthesis of 2-phenylbenzoxazoles by potassium cyanide assisted reaction of *o*-aminophenols and benzaldehydes. *Tetrahedron Lett.* **52**, 308–310 (2011).

9. Vosooghi, M., Saeedi, M., Mahdavi, M., Jafapour, F., Shafiee, A., Foroumadi, Al. A novel and efficient route for the synthesis of 5-nitrobenzo[*d*]oxazole derivatives. *J. Fluor. Chem.* **161**, 83–86 (2014).
10. Yalçın, İ., Şener, E., Özden, T., Özden, S., Akın, A. Synthesis and microbiological activity of 5-methyl-2-[*p*-substituted phenyl] benzoxazoles. *Eur. J. Med. Chem.* **25**, 705–708 (1990).
11. Nguyen, L. A., Ngo, Q. A., Retailleau, P., Nguyen, T. B. Elemental sulfur as a polyvalent reagent in redox condensation with *o*-chloronitrobenzenes and benzaldehydes: three-component access to 2-arylbenzothiazoles. *Green Chem.* **19**, 4289–4293 (2017).
12. Azizian, J., Torabi, P., Noei, J. Synthesis of benzimidazoles and benzoxazoles using TiCl₃OTf in ethanol at room temperature. *Tetrahedron Lett.* **57**, 185–188 (2016).